Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan...
https://pubmed.ncbi.nlm.nih.gov/41403476/Actively Recruiting
Led by Takeda · Updated on 2026-05-27
396
Participants Needed
138
Research Sites
60 weeks
Total Duration
Researchers are evaluating whether combining vedolizumab and upadacitinib, called dual targeted therapy DTT, reduces bowel inflammation and ulcers more effectively than vedolizumab alone in adults with moderately to severely active Crohns Disease CD. The study also compares the safety and effectiveness of these treatments. This Phase 3b trial is conducted worldwide and sponsored by Takeda, enrolling about 396 participants. Participants are randomly assigned to receive either vedolizumab with upadacitinib or vedolizumab with a placebo for 12 weeks during the Induction Phase. Vedolizumab is given as a 300 mg intravenous infusion at Weeks 0, 2, 6, and 10 upadacitinib or placebo is taken daily by mouth. Those who respond to treatment at Week 12 will continue with vedolizumab alone every 8 weeks for 40 weeks in the Maintenance Phase. Vedolizumab dosing frequency may increase to every 4 weeks if needed. During the approximately 70-week study, participants visit the clinic 15 times for assessments including clinical evaluations, endoscopic exams, and patient-reported outcomes. Researchers measure clinical remission, endoscopic response, and safety outcomes at Week 12 and Week 52. There is also an 18-week safety follow-up after the maintenance period to monitor participants health.
CONDITIONS
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
T
Takeda Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Takeda
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dual-targeted induction then vedolizumab maintenance | Vedolizumab induction plus placebo then vedolizumab maintenance | Established vedolizumab biologic therapy |
|---|---|---|---|
| What it is | Induction with vedolizumab plus upadacitinib followed by vedolizumab maintenance | Induction with vedolizumab plus placebo followed by vedolizumab maintenance | Vedolizumab monotherapy is an established biologic treatment for moderate‑to‑severe Crohn’s disease |
| Role in the trial | Experimental induction regimen evaluated for added benefit | Control induction regimen representing vedolizumab monotherapy | Current standard biologic therapy in this patient population |
| Primary use | To induce remission by combining two advanced therapies then maintain disease control with vedolizumab | To induce remission with vedolizumab alone and maintain with continued monotherapy | Induce and maintain remission with vedolizumab monotherapy |
| How it is given | Vedolizumab infusions for induction and maintenance combined with upadacitinib tablets during induction | Vedolizumab infusions for induction and maintenance with placebo tablets during induction | Vedolizumab given as standard induction and maintenance infusion regimen |
| Evidence status | Efficacy and safety are being evaluated; results not yet available | Well‑established efficacy of vedolizumab induction and maintenance from prior studies | Evidence supports vedolizumab monotherapy as effective induction and maintenance agent |
| Important risks | Not yet established; safety under evaluation | Risks typical of vedolizumab infusions (infections, infusion reactions); well‑characterized profile | Vedolizumab safety profile is established with gut‑selective integrin inhibition (infection risk, infusion reactions) |
| Important limitations | Dual-targeted therapy may increase risk of adverse events; cost and complexity are unknown until outcomes are reported | Vedolizumab induction may have slower onset of effect compared with some agents | Monotherapy may be less effective in patients with prior advanced treatment exposure |
| Patient impact | Not yet known until trial outcomes are reported | Vedolizumab monotherapy has demonstrated improvements in remission and mucosal healing | Established benefits include symptom control and endoscopic inflammation reduction |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive vedolizumab intravenous infusion combined with either upadacitinib or placebo orally once daily for 12 weeks to reduce Crohn's disease activity.
4 infusion visits at Weeks 0, 2, 6, and 10; daily oral medication
Duration - 40 weeks
Participants who respond to induction treatment continue vedolizumab monotherapy with intravenous infusions every 8 weeks, which may be escalated to every 4 weeks based on clinical decision, for maintenance of disease control.
Intravenous infusion visits every 8 weeks starting at Week 14
Duration - 18 weeks
Participants are monitored for safety and adverse effects after completing the maintenance treatment phase.
Periodic safety assessments up to Week 70
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Silvio Danese, Bruce E Sands, Brian G Feagan...
https://pubmed.ncbi.nlm.nih.gov/41403476/Takeda
Lead Sponsor